-
1 Comment
Yungjin Pharm. Co., Ltd is currently in a long term downtrend where the price is trading 13.1% below its 200 day moving average.
From a valuation standpoint, the stock is 38.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.3.
Yungjin Pharm. Co., Ltd's total revenue sank by 5.0% to $51B since the same quarter in the previous year.
Its net income has increased by 19.3% to $-2B since the same quarter in the previous year.
Finally, its free cash flow grew by 190.6% to $5B since the same quarter in the previous year.
Based on the above factors, Yungjin Pharm. Co., Ltd gets an overall score of 3/5.
| Exchange | KO |
|---|---|
| CurrencyCode | KRW |
| ISIN | KR7003520004 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.94 |
|---|---|
| PE Ratio | None |
| Market Cap | 371B |
| Target Price | None |
| Dividend Yield | None |
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. The company also provides vitamins, minerals, and other products; and APIs. Yungjin Pharm. Co., Ltd. was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 003520.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
